4-Acridinecarboxamide, 9-amino-N-[2-(dimethylamino)ethyl]-5-methyl- | 89459-51-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-Acridinecarboxamide, 9-amino-N-[2-(dimethylamino)ethyl]-5-methyl-
• 英文别名: 9-amino-N-[2-(dimethylamino)ethyl]-5-methylacridine-4-carboxamide
• CAS: 89459-51-8
• 化学式: C₁₉H₂₂N₄O
• 分子量: 322.41
• InChiKey: GZQOFEOTVUDSLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  71.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  9-chloro-4-methylacridine-5-dimethylaminoethylcarboxamide 在 氨 作用下， 以 various solvent(s) 为溶剂， 反应 0.25h， 生成 4-Acridinecarboxamide, 9-amino-N-[2-(dimethylamino)ethyl]-5-methyl-
  参考文献：
  名称：

  Potential antitumor agents. 46. Structure-activity relationships for acridine monosubstituted derivatives of the antitumor agent N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide

  摘要：

  A series of monosubstituted derivatives of the new antitumor agent N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide has been prepared, bearing methyl, methoxy, and chloro groups at available acridine positions. The physicochemical properties and antitumor activity of these compounds varied more with the position than with the nature of the substituent groups. The highest levels of both in vitro and in vivo antileukemic activity were shown by 5-substituted derivatives, while 7- and 8-substituted derivatives possessed the highest selectivity toward the HCT-8 human colon carcinoma line compared to the L1210 mouse leukemia line in vitro.

  DOI：

  10.1021/jm00154a008

文献信息

• Radiation-activated cytotoxin therapy
  申请人：AUCKLAND UNISERVICES LIMITED

  公开号：EP1225169A1

  公开（公告）日：2002-07-24

  A method of treating neoplastic disease which comprises the steps of: (a) administering to a patient in need of such treatment an effective amount of a radiation-activated cytotoxin prodrug (RACP) which has low toxicity, which can be reduced by reducing agents generated by the radiolysis of water (the equated electron and/or the hydrogen radical) and which, upon reduction, releases a sufficient amount of an effector of sufficient cytotoxic potency to kill tumour cells; and (b) irradiating said tumour cells to reduce the prodrug which is present at the locus of said tumour cells to release said cytotoxic effector. In preferred embodiments, the RACP is of formula (I), (VI), (VII) or (VIII).

  一种治疗肿瘤性疾病的方法，包括以下步骤 (a) 给需要这种治疗的病人服用有效量的辐射活化细胞毒素原药(RACP)，该原药毒性低，可被水的辐射分解产生的还原剂(等价电子和/或氢自由基)还原，还原后释放出足够量的具有足够细胞毒性效力的效应物，以杀死肿瘤细胞；以及 (b) 对所述肿瘤细胞进行辐照，以还原存在于所述肿瘤细胞部位的原药，从而释放所述细胞毒性效应物。 在优选的实施方案中，RACP 是式 (I)、(VI)、(VII) 或 (VIII)。
• REWCASTLE, G. W.;ATWELL, G. J.;CHAMBERS, D.;BAGULEY, B. C.;DENNY, W. A., J. MED. CHEM., 1986, 29, N 4, 472-477
  作者：REWCASTLE, G. W.、ATWELL, G. J.、CHAMBERS, D.、BAGULEY, B. C.、DENNY, W. A.

  DOI：——

  日期：——
• RADIATION-ACTIVATED CYTOTOXIN THERAPY
  申请人：AUCKLAND UNISERVICES LIMITED

  公开号：EP0850224A1

  公开（公告）日：1998-07-01
• US6071908A
  申请人：——

  公开号：US6071908A

  公开（公告）日：2000-06-06
• [EN] RADIATION-ACTIVATED CYTOTOXIN THERAPY<br/>[FR] THERAPIE A BASE DE CYTOTOXINE ACTIVEE PAR RAYONNEMENT
  申请人：AUCKLAND UNISERVICES LIMITED

  公开号：WO1997007101A1

  公开（公告）日：1997-02-27

  (EN) A method of treating neoplastic disease which comprises the steps of: (a) administering to a patient in need of such treatment an effective amount of a radiation-activated cytotoxin prodrug (RACP) which has low toxicity, which can be reduced by reducing agents generated by the radiolysis of water (the equated electron and/or the hydrogen radical) and which, upon reduction, releases a sufficient amount of an effector of sufficient cytotoxic potency to kill tumour cells; and (b) irradiating said tumour cells to reduce the prodrug which is present at the locus of said tumour cells to release said cytotoxic effector. In preferred embodiments, the RACP is of formula (I), (VI), (VII) or (VIII).(FR) Cette invention concerne un procédé de traitement des maladies néoplasiques qui consiste (a) à administrer à un patient nécessitant un tel traitement une quantité efficace d'un précurseur de médicament à base de cytotoxine activée par rayonnement (RACP) qui présente une faible toxicité, qui peut être réduit par des agents réducteurs produits par radiolyse de l'eau (l'électron hydraté et/ou le radical hydrogène) et qui, lors de sa réduction, libère une quantité suffisante d'un effecteur possédant un pouvoir cytotoxique suffisant pour détruire les cellules tumorales, et (b) à irradier lesdites cellules tumorales afin de réduire le précurseur de médicament qui est présent au niveau du locus desdites cellules tumorales de façon à ce qu'il libère ledit effecteur cytotoxique. Dans les réalisations préférées de l'invention, le précurseur RACP est représenté par l'une des formules (I), (VI), (VII) ou (VIII).